Gemcitabine-based adjuvant chemotherapy for patients with advanced gallbladder cancer

Masafumi Nakamura; Hiroshi Nakashima; Toshiya Abe; Takaaki Ensako; Koji Yoshida; Keisuke Hino

Gemcitabine-based adjuvant chemotherapy for patients with advanced gallbladder cancer

Masafumi Nakamura, Hiroshi Nakashima, Toshiya Abe, Takaaki Ensako, Koji Yoshida, Keisuke Hino

Research output: Contribution to journal › Article › peer-review

Abstract

Aim: We investigated effects of gemcitabine-based adjuvant chemotherapy (GEM) on prognosis of patients with gallbladder cancer. Patients and Methods: We retrospectively analyzed outcomes of 36 patients who underwent radical resection for gallbladder cancer from 2001 through to 2012, using² for prognostic factors and Kaplan-Meier estimator and log-rank tests for survival data. Results: The GEM group had higher rates of lymph node positivity and distant metastasis, higher UICC stage and fewer R0 resections; their 5-year survival rate (60%) did not significantly differ from that of the controls (70.0%), nor was GEM a significant prognostic factor in univariate analysis. However, among patients who underwent R1 and R2 resections, GEM significantly improved prognosis in both univariate and multivariate analyses. Median survival of the R1/2 GEM group (66.4 months) was significantly better than that of controls (5.4 months) (p=0.002). Conclusion: GEM improved prognosis of patients with gallbladder cancer after R1/R2 resections.

Original language	English
Pages (from-to)	3125-3130
Number of pages	6
Journal	Anticancer research
Volume	34
Issue number	6
Publication status	Published - Jun 1 2014
Externally published	Yes

All Science Journal Classification (ASJC) codes

Oncology
Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Cite this

@article{a479aafb982e41d483d8c1f904c7e2bf,

title = "Gemcitabine-based adjuvant chemotherapy for patients with advanced gallbladder cancer",

abstract = "Aim: We investigated effects of gemcitabine-based adjuvant chemotherapy (GEM) on prognosis of patients with gallbladder cancer. Patients and Methods: We retrospectively analyzed outcomes of 36 patients who underwent radical resection for gallbladder cancer from 2001 through to 2012, using2 for prognostic factors and Kaplan-Meier estimator and log-rank tests for survival data. Results: The GEM group had higher rates of lymph node positivity and distant metastasis, higher UICC stage and fewer R0 resections; their 5-year survival rate (60%) did not significantly differ from that of the controls (70.0%), nor was GEM a significant prognostic factor in univariate analysis. However, among patients who underwent R1 and R2 resections, GEM significantly improved prognosis in both univariate and multivariate analyses. Median survival of the R1/2 GEM group (66.4 months) was significantly better than that of controls (5.4 months) (p=0.002). Conclusion: GEM improved prognosis of patients with gallbladder cancer after R1/R2 resections.",

author = "Masafumi Nakamura and Hiroshi Nakashima and Toshiya Abe and Takaaki Ensako and Koji Yoshida and Keisuke Hino",

year = "2014",

month = jun,

day = "1",

language = "English",

volume = "34",

pages = "3125--3130",

journal = "Anticancer Research",

issn = "0250-7005",

publisher = "International Institute of Anticancer Research",

number = "6",

}

TY - JOUR

T1 - Gemcitabine-based adjuvant chemotherapy for patients with advanced gallbladder cancer

AU - Nakamura, Masafumi

AU - Nakashima, Hiroshi

AU - Abe, Toshiya

AU - Ensako, Takaaki

AU - Yoshida, Koji

AU - Hino, Keisuke

PY - 2014/6/1

Y1 - 2014/6/1

N2 - Aim: We investigated effects of gemcitabine-based adjuvant chemotherapy (GEM) on prognosis of patients with gallbladder cancer. Patients and Methods: We retrospectively analyzed outcomes of 36 patients who underwent radical resection for gallbladder cancer from 2001 through to 2012, using2 for prognostic factors and Kaplan-Meier estimator and log-rank tests for survival data. Results: The GEM group had higher rates of lymph node positivity and distant metastasis, higher UICC stage and fewer R0 resections; their 5-year survival rate (60%) did not significantly differ from that of the controls (70.0%), nor was GEM a significant prognostic factor in univariate analysis. However, among patients who underwent R1 and R2 resections, GEM significantly improved prognosis in both univariate and multivariate analyses. Median survival of the R1/2 GEM group (66.4 months) was significantly better than that of controls (5.4 months) (p=0.002). Conclusion: GEM improved prognosis of patients with gallbladder cancer after R1/R2 resections.

AB - Aim: We investigated effects of gemcitabine-based adjuvant chemotherapy (GEM) on prognosis of patients with gallbladder cancer. Patients and Methods: We retrospectively analyzed outcomes of 36 patients who underwent radical resection for gallbladder cancer from 2001 through to 2012, using2 for prognostic factors and Kaplan-Meier estimator and log-rank tests for survival data. Results: The GEM group had higher rates of lymph node positivity and distant metastasis, higher UICC stage and fewer R0 resections; their 5-year survival rate (60%) did not significantly differ from that of the controls (70.0%), nor was GEM a significant prognostic factor in univariate analysis. However, among patients who underwent R1 and R2 resections, GEM significantly improved prognosis in both univariate and multivariate analyses. Median survival of the R1/2 GEM group (66.4 months) was significantly better than that of controls (5.4 months) (p=0.002). Conclusion: GEM improved prognosis of patients with gallbladder cancer after R1/R2 resections.

UR - http://www.scopus.com/inward/record.url?scp=84906324031&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84906324031&partnerID=8YFLogxK

M3 - Article

C2 - 24922682

AN - SCOPUS:84906324031

SN - 0250-7005

VL - 34

SP - 3125

EP - 3130

JO - Anticancer Research

JF - Anticancer Research

IS - 6

ER -

Gemcitabine-based adjuvant chemotherapy for patients with advanced gallbladder cancer

Abstract

All Science Journal Classification (ASJC) codes

UN SDGs

Other files and links

Fingerprint

Cite this